GlassScriptPhysician profile
Joseph Walton
NPI 1003808213
$5,933.22
in general payments reported to CMS, 2019-2025
43 companies · $587 in 2025
The $587 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,100 · 2020: $602 · 2021: $935 · 2022: $686 · 2023: $1,006 · 2024: $1,018 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,396 · Travel and Lodging: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,395.64 |
| Travel and Lodging | $214.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $633.73 | 2019-2025 | Brilinta, Farxiga, Lokelma |
| Amgen INC. | $515.60 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $491.62 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $446.21 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $400.15 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $382.17 | 2021-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $332.43 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $248.42 | 2019-2025 | Eliquis, Camzyos |
| Medtronic, INC. | $240.17 | 2021-2024 | Linq II |
| Shockwave Medical, INC | $228.51 | 2020-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Sanofi-Aventis U.S. LLC | $220.01 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $196.37 | 2020-2023 | Uptravi, Opsumit |
| Daiichi Sankyo INC. | $188.50 | 2019-2023 | Injectafer |
| Abbott Laboratories | $120.28 | 2019-2020 | |
| Abiomed | $96.44 | 2019-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Walton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.